Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Protalix Biotherapeutics Inc PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:PLX)

Protalix BioTherapeutics to Present Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018

GlobeNewswire September 17, 2018

Protalix BioTherapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire August 23, 2018

Protalix BioTherapeutics Appoints David Granot to its Board of Directors

GlobeNewswire August 13, 2018

Protalix BioTherapeutics Reports 2018 Second Quarter Results and Provides Corporate Update

GlobeNewswire August 9, 2018

Protalix BioTherapeutics to Hold Second Quarter 2018 Financial Results and Corporate Update Conference Call on August 9, 2018

GlobeNewswire July 31, 2018

Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

GlobeNewswire July 24, 2018

Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

GlobeNewswire June 5, 2018

Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress

GlobeNewswire May 25, 2018

Protalix Announces Exchange and Discharge of Remaining 2018 Notes

GlobeNewswire May 24, 2018

Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update

GlobeNewswire May 9, 2018

Protalix Biotherapeutics, Inc. to Host Earnings Call

Accesswire March 6, 2018

The Biotechnology Market is Projected to Grow

PR Newswire January 26, 2018

Biotech and Pain Management Therapeutics Segments Projected to Grow

PR Newswire January 12, 2018

Global Biotechnology Market Showing Potential for Further Growth

PR Newswire November 21, 2017

Investor Network: Protalix BioTherapeutics, Inc. to Host Earnings Call

Accesswire August 9, 2017

Today's Research Report Coverage on Biotech Stocks -- Rexahn Pharma, Protalix BioTherapeutics, Navidea Biopharma, and Biostage

PR Newswire July 19, 2017

Biotech Stocks Under Scanner -- Rexahn Pharma, Peregrine Pharma, Immunomedics, and Protalix BioTherapeutics

PR Newswire May 8, 2017

FinancialBuzz.com: Advances in Technology Applied in the Biotech Sector

PR Newswire January 30, 2017

Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017

GlobeNewswire January 9, 2017

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com January 3, 2017